GSK’s depemokimab shows strong potential for United States Food and Drug Administration approval in asthma and chronic ...

Faulty versions of the LMNA gene can cause a wide range of health problems, including heart muscle disease (dilated ...

One study examines the small molecular cardiac myosin inhibitor for safety and efficacy at 96 weeks, and another compares it ...

Bristol Myers Squibb (BMS) today announced the launch of Kopozgo® (Mavacamten) in India -- the first and only oral, selective cardiac myosin inhibitor approved in the country for the treatment of ...

In a phase 2b trial, danicamtiv, a novel cardiac myosin activator, was well tolerated and associated with improved heart ...

Well, currently we have three FDA approved therapies for the management of transthyretin cardiac amyloidosis, and two of those belong to the category of stabilizers and the one and the most recent one ...

Shares of Lexeo Therapeutics rose in off-hours trading after the company reported progress in discussions with the Food and Drug Administration regarding the accelerated approval pathway for its ...

The UB faculty member, mong the top researchers in pediatric cardiomyopathy, is credited with establishing the pediatric ...

Learn about the complications of hypertrophic cardiomyopathy (HCM), including arrhythmias, heart block, and heart failure, as ...

The hereditary transthyretin amyloidosis market is experiencing significant growth driven by increasing disease awareness, ...

Beta-blockers have been the cornerstone of treatment for obstructive hypertrophic cardiomyopathy for almost 6 years. Recent ...

U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to ...